Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem Cell Transplantation

Table 1

Clinical characteristics of study patients ().

Patient characteristics		%
Gender
Female	168	44.6
Male	209	55.4
Age at HSCT
35	139	36.9
35	238	63.1
EBMT risk score
2	155	41.1
2	222	58.9
Indication for HSCT
AML/MDS	157	41.7
MPD	19	5.0
ALL	74	19.6
Lymphoma	63	16.7
MM	18	4.8
SAA	45	11.9
Others	1	0.3
Donor relation
Matched sibling	181	48.0
Nonmatched sibling	196	52.0
Conditioning regimen
TBI-12 Gy based	125	33.2
Fludarabine based	74	19.6
Myeloablative	248	65.8
Type 2 DM history	15	4.0
Smoking history	24	6.4
Posttransplant CMV reactivation
Within 1 year	188	49.9
Within 2 years	190	50.4
PTLD after HSCT
Within 1 year	14	3.7
Within 2 years	15	4.0

HSCT: hematopoietic stem cell transplantation; MDS: myelodysplastic syndromes; EBMT: European Group for Blood and Marrow Transplantation; AML: acute myeloid leukemia; MPD: myeloproliferative disorder; ALL: acute lymphoblastic leukemia; MM: multiple myeloma; SAA: severe aplastic anemia; TBI: total body irradiation; CMV: cytomegalovirus; DM: diabetes mellitus; PTLD: posttransplant lymphoproliferative disorder.